Transverse myelitis in primary Sjögren's syndrome: Usefulness of low-dose oral cyclophosphamide rather than pulse therapy [1]

Scandinavian Journal of Rheumatology

Volumn 35, Issue 5, 2006, Pages 409-410

  Quartuccio, L ^a   Ferraccioli, G F ^b   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; PREDNISONE; STEROID;

ADULT; BLADDER INJURY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LETTER; LOW DRUG DOSE; MYELITIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; SCINTIGRAPHY; SJOEGREN SYNDROME; SYMPTOM; URINE INCONTINENCE; WEAKNESS;

ADMINISTRATION, ORAL; AGED; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MYELITIS, TRANSVERSE; PULSE THERAPY, DRUG; SJOGREN'S SYNDROME;

EID: 33750172588     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740600588301     Document Type: Letter

References (10)

1. Vincent TL, Richardson MP, Mackworth-Young CG, Hawke SH, Venables PJW. Sjögren's syndrome myelopathy: response to immunosuppressive treatment. Am J Med 2003;114:145-8.
2. Menage P, de Toffol B, Degenne D, Saudeau D, Bardos P, Autret A. Gougerot-Sjogren syndrome. Central neurological involvement with recurrent development] in French. Rev Neurol 1993;149:554-6.
3. Wright R, O'Duffy J, Rodriguez M. Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy. Neurology 1999;52:386-8.
4. Williams CS, Butler E, Román GC. Treatment of myelopathy in Sjögren's syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001;58:815-19.
5. Hermisson M, Klein R, Schmidt F, Weller M, Kuler W. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand 2002;105:450-3.
6. Hawley RJ, Hendricks WT. Treatment of Sjogren syndrome myelopathy with azathioprine and steroids. Arch Neurol 2002;59:875.
7. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996;55:116-21.
8. Rogers SJ, Williams CS, Román GC. Myelopathy in Sjögren's syndrome. Role of nonsteroidal immunosuppressants. Drugs 2004;64:123-32.
9. Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Clin Dis North Am 1993;19:869-908.
10. Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, et al. Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994;44:899-908.